|Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone.|
|Jump to Full Text|
|PMID: 23335094 Owner: NLM Status: PubMed-not-MEDLINE|
|Prostate cancer (PC) bone metastases show weak responses to conventional therapies. Bone matrix is rich in growth factors, with insulin-like growth factor-1 (IGF-1) being one of the most abundant. IGF-1 acts as a survival factor for tumor cells and we speculate that bone-derived IGF-1 counteracts effects of therapies aimed to target bone metastases and, consequently, that therapeutic effects could be enhanced if given in combination with IGF-1 receptor (IGF-1R) inhibitors. Simvastatin inhibits the mevalonate pathway and has been found to induce apoptosis of PC cells. The aims of this study were to confirm stimulating effects of bone-derived IGF-1 on PC cells and to test if IGF-1R inhibition enhances growth inhibitory effects of simvastatin on PC cells in a bone microenvironment. The PC-3 and 22Rv1 tumor cell lines showed significantly induced cell growth when co-cultured with neonatal mouse calvarial bones. The tumor cell IGF-1R was activated by calvariae-conditioned media and neutralization of bone-derived IGF-1 abolished the calvarium-induced PC-3 cell growth. Treatment of PC-3 and 22Rv1 cells with simvastatin, or the IGF-1R inhibitor NVP-AEW541, reduced tumor cell numbers and viability, and induced apoptosis. Combined simvastatin and NVP-AEW541 treatment resulted in enhanced growth inhibitory effects compared to either drug given alone. Effects of simvastatin involved down-regulation of IGF-1R in PC-3 and of constitutively active androgen receptor variants in 22Rv1 cells. In conclusion, we suggest that IGF-1 inhibition may be a way to strengthen effects of apoptosis-inducing therapies on PC bone metastases; a possibility that needs to be further tested in pre-clinical models.|
|Annika Nordstrand; Marie Lundholm; Andreas Larsson; Ulf H Lerner; Anders Widmark; Pernilla Wikström|
Related Documents :
|21437644 - Establishment and maintenance of compartmental boundaries: role of contractile actomyos...
25050214 - Screening of novel immunogenic cell death inducers within the nci mechanistic diversity...
24221594 - Reduced intracellular content of methotrexate in an isolated mtx-resistant cell line of...
23336074 - Wnt/β-catenin signaling cell-autonomously converts non-hepatic endodermal cells to a l...
6539254 - Selective binding of human cumulus cell-secreted glycoproteins to human spermatozoa dur...
21437644 - Establishment and maintenance of compartmental boundaries: role of contractile actomyos...
|Type: Journal Article Date: 2013-01-22|
|Title: Cancer microenvironment : official journal of the International Cancer Microenvironment Society Volume: 6 ISSN: 1875-2292 ISO Abbreviation: Cancer Microenviron Publication Date: 2013 Dec|
|Created Date: 2013-12-09 Completed Date: 2013-12-09 Revised Date: 2013-12-16|
Medline Journal Info:
|Nlm Unique ID: 101322634 Medline TA: Cancer Microenviron Country: Netherlands|
|Languages: eng Pagination: 231-40 Citation Subset: -|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): Cancer Microenviron
Journal ID (iso-abbrev): Cancer Microenviron
Publisher: Springer Netherlands, Dordrecht
© The Author(s) 2013
Received Day: 8 Month: 10 Year: 2012
Accepted Day: 8 Month: 1 Year: 2013
Electronic publication date: Day: 22 Month: 1 Year: 2013
pmc-release publication date: Day: 22 Month: 1 Year: 2013
collection publication date: Month: 12 Year: 2013
Volume: 6 Issue: 3
First Page: 231 Last Page: 240
PubMed Id: 23335094
Publisher Id: 129
|Inhibition of the Insulin-Like Growth Factor-1 Receptor Enhances Effects of Simvastatin on Prostate Cancer Cells in Co-Culture with Bone|
|Ulf H. LernerAff4Aff5|
Address: +46-90-7853752 +46-90-7852829 email@example.com
Department of Radiation Sciences, Oncology, Umeå University, 901 85 Umeå, Sweden
Department of Medical Biosciences, Pathology, Umeå University, 901 85 Umeå, Sweden
Department of Chemistry, Umeå University, Umeå, Sweden
Department of Molecular Periodontology, Umeå University, Umeå, Sweden
Centre for Bone and Arthritis Research at Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
The skeleton is the most frequent site for metastases of prostate cancer (PC) , and as there are no curable treatments for metastatic disease there is a great need for new therapeutic strategies targeting bone metastases. The mineralized bone matrix contains a wide range of growth factors, where insulin-like growth factor-1 (IGF-1) is one of the most abundant . When metastases are formed in the bone they activate osteoclastic bone resorption and growth factors such as IGF-1 and transforming growth factor-β (TGF-β) are released into the bone marrow cavity where they influence the metastatic tumor cells. Although PC bone metastases generally form sclerotic metastases, the bone metastasis process also includes a lytic component . Accordingly, we previously showed that PC cells were able to induce lytic activity of bone, and the release of bone-derived IGF-1, when grown in co-culture with calvariae . There is increasing evidence that the IGF family is involved in the development and progression of many cancer types, including PC. Several studies have shown that a high concentration of circulating IGF-1 is associated with an increased risk of PC [5, 6], and overexpression of the IGF-1 receptor (IGF-1R) has been observed in prostate tumors and metastases [7–11]. The IGF-1R is a receptor tyrosine kinase (RTK) that upon activation by IGF-1 shows mitogenic and anti-apoptotic effects [12, 13], and is believed to be important for oncogenic transformation (reviewed in ). Inhibition of the IGF-1R has been shown to impair tumor cell growth in vitro and in vivo (reviewed in )
Since IGF-1 is a strong survival factor for tumor cells we speculate that effects of apoptosis-inducing cancer therapies, such as castration, given with the intention to treat PC bone metastases, are possibly attenuated by high IGF-1 levels in the bone environment. Furthermore, we believe that effects of those therapies could be enhanced if given in combination with IGF-R1 inhibition. A number of strategies to target IGF-1R signaling have been tested in clinical trials, including neutralizing IGF-1 antibodies, anti-sense and RNA interference strategies to the IGF-1R, and inhibition of IGF-1R signaling by antibodies or tyrosine kinase inhibitors (reviewed in ).
We have previously found that PC bone metastases contain high levels of cholesterol . Furthermore, it has been shown that cholesterol targeting drugs; statins, are able to induce apoptosis of PC cells in vitro [18, 19]. Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors targeting the rate-limiting step of cholesterol synthesis, and have been prescribed during the last decades for prevention of cardiovascular diseases. Large epidemiological studies have indicated that statins may also reduce the risk of developing PC, particularly in its aggressive forms, although results are not completely conclusive (reviewed in ). The aim of this study was to confirm stimulating effects of bone-derived IGF-1 on PC cells in an in vitro model for tumor cell and bone cell interactions, and furthermore to test if IGF-1R inhibition could enhance growth inhibitory effects of simvastatin on PC cells in this model system.
To determine if prostate tumor cells show increased growth in a bone microenvironment, PC-3 and 22Rv1 cell lines were co-cultured with mice calvariae in a two-chamber in vitro model as previously described in Nordstrand et al. . After 72 h in co-culture, the number of PC-3 and 22Rv1 cells was increased 1.2-fold compared to cell numbers observed when the tumor cell lines were cultured without calvariae (P = 1.2 × 10−5 and 3.6 × 10−5, respectively, Fig. 1), suggesting that bone-derived factors were favoring the growth of the tumor cells.
To identify calvariae-derived factors with possible growth-promoting effects on PC cells, the phosphorylation status of 42 RTKs in PC-3 and 22Rv1 cells were analyzed before and after stimulation with calvariae-conditioned media. The IGF-1R was one of the most clearly activated RTKs by calvariae-conditioned media, showing 5.6 and 2.9 times increased phosphorylation levels in PC-3 and 22Rv2 cells, respectively (Supplemental Fig. S1). Moreover, mean levels of mouse IGF-1 (calvarial-derived IGF-1) were increased 1.6 and 1.4 times in the media when calvariae were co-cultured with PC-3 and 22Rv1 cells for 72 h, respectively, as compared to the mean control IGF-1 level (1,800 pg/ml) reached when calvariae were cultured without tumor cells (P = 2.7 × 10−5 and 6.1 × 10−3, Fig. 2). No IGF-1 was detected in conditioned media from tumor cells cultured without calvariae (data not shown), indicating the mouse specificity of the ELISA used. Very low levels (<94 pg/ml) of human IGF-1 were detected in the conditioned media from PC-3 and 22Rv1 tumor cells cultured alone, and there was no induction of either IGF-1 mRNA in the tumor cells or of human IGF-1 protein in the media after 72 h in co-culture with calvariae (data not shown), which is in line with previous results shown for PC-3 and LNCaP cells . From these results we hypothesized that PC cells in co-culture with mice calvariae were able to induce release of bone-derived IGF-1 into the surrounding, resulting in subsequent activation of the IGF-1R in tumor cells and stimulation of tumor cell growth.
To examine if the growth stimulatory effects on tumor cells observed in co-culture with calvariae could be explained by the release of IGF-1 from bone, we added excess of a neutralizing antibody against mouse IGF-1 to the media. Results showed that when mouse IGF-1 was neutralized, the bone-derived effect on PC-3 cell numbers was completely abolished, while in 22Rv1 it was not significantly reduced (P = 0.60) indicating that calvariae-derived factors other than IGF-1 significantly affected 22Rv1 growth (Fig. 1b). Notably, the neutralizing antibody for mouse IGF-1 had no direct effect on tumor cells grown in absence of mouse calvariae (Fig. 1).
To further investigate the role of IGF-R1 signaling in this system, the small molecule IGF-1R kinase inhibitor NVP-AEW541 [21, 22] was used to inhibit PC-3 and 22Rv1 cells. The tumor cell viability after 72 h of NVP-AEW541 treatment was significantly decreasing with increasing drug concentrations (0–12 μM, data not shown). Accordingly, when PC-3 and 22Rv1 cells were treated with simvastatin at increasing concentrations (0–30 μM) for 72 h significantly decreased cell viability was observed (data not shown). To examine the combined effect of simvastatin and NVP-AEW541, the drugs were administrated together in the combination of 10 μM simvastatin and 3 μM NVP-AEW541 (Fig. 3). The viability of PC-3 and 22Rv1 cells incubated for 72 h with 10 μM simvastatin was decreased to 34 and 69 %, respectively, compared to untreated cells (P = 5.7 × 10−7 and 6.5 × 10−6), while the viabilities were reduced to 53 and 73 % when the two tumor cell lines were treated with 3 μM NVP-AEW541 (P = 5.6 × 10−6 and 1.6 × 10−5). The lowest cell viabilities; 19 and 29 % for PC-3 and 22Rv1 cells, respectively, were obtained after the combined treatment of cells with 10 μM simvastatin and 3 μM NVP-AEW541 for 72 h (P = 3.7 × 10−5 and 5.4 × 10−7 in comparison to simvastatin treatment, P = 8.0 × 10−7 and 3.5 × 10−7 in comparison to NVP-AEW541 treatment, Fig. 3).
Also when tumor cells were co-cultured with calvariae, the combination of 3 μM NVP-AEW541 and 10 μM simvastatin resulted in enhanced effects compared to effects of either drug when administrated alone. Total number of tumor cells was determined after 72 h, and the combination of IGF-1R inhibition together with simvastatin treatment resulted in 33 and 30 % viable PC-3 and 22Rv1 cells, respectively (P = 0.042 and 0.046 in comparison to simvastatin treatment, P = 3.1 × 10−4 and 2.1 × 10−8 in comparison to NVP-AEW541 treatment, Fig. 3). Accordingly, the pro-apoptotic effects on PC-3 and 22Rv1 cells in co-culture with calvariae were clearly higher when NVP-AEW541 and simvastatin were given in combination than when given as single agents (Fig. 4).
Statins have previously been shown to cause down-regulation of IGF-1R expression in tumor cells [23, 24]. The tumor cell IGF-1R mRNA and proteins levels were therefore examined in co-cultures with calvariae in response to 10 μM simvastatin and 3 μM NVP-AEW541 treatment for 72 h. Simvastatin alone or in combination with NVP-AEW541 reduced the IGF-1R mRNA levels about 0.7-fold (P = 6.1 × 10−4 and P = 2.6 × 10−3) in PC-3 but not 22Rv1 cells (Fig. 5a). Accordingly, the IGF-1R protein levels in PC-3 cells were decreased by simvastatin and NVP-AEW541 treatment, while the levels in 22Rv1 cells were not clearly reduced (Fig. 5b–d). In contrast, NVP-AEW541 stimulated a 1.6-fold (P = 1.6 × 10−3) increase of IGF-1R mRNA levels and a slight increase of IGF-1R protein levels in the 22Rv1 cells (Fig. 5a, c, d).
In 22Rv1 cells we hypothesized that simvastatin might affect expression of the androgen receptor (AR), as previously described for prostate cells . In addition to the full length AR (ARfl), the 22Rv1 cells are known to express a series of alternatively spliced AR variants (AR-Vs) with molecular weights of approximately 75–80 kDa, including the AR-V7 (reviewed in ). We found that simvastatin treatment resulted in approximately 50 % reductions of the AR-V7 mRNA and of the AR-V proteins, while the ARfl was not down-regulated (Fig. 6).
In this study, using an in vitro model for PC and bone cell interactions, we show that bone-released IGF-1 creates a favorable micro-environment for PC cells. Through neutralization of bone-derived IGF-1 we observed that bone-induced stimulation of tumor cell growth was completely abolished in the lytic PC-3 cells while not significantly attenuated in the more sclerotic 22Rv1 cells. Both cell lines were however inhibited by the IGF-1R inhibitor NVP-AEW541, indicating possible autocrine stimulation of the IGF-1R in the tumor cells and/or transactivation of the IGF-1R by other ligands. Importantly, the combined use of IGF-1R inhibition and simvastatin resulted in a more intense apoptotic stimuli in both tumor cell lines than either of the drugs administrated alone. We therefore speculate that not only lytic but also sclerotic PC bone metastases would benefit from IGF-1R inhibition given with the intention to reduce IGF-1R survival effects during administration of apoptosis-inducing therapies, e.g. castration therapy.
Castration therapy of PC acts by reducing the levels of circulating androgens in the patients, and this in turn results in reduced proliferation and increased apoptosis of PC cells . The precise mechanism behind apoptosis induction in the prostate and in prostate tumors after androgen ablation is not fully understood, but the general idea is that epithelial cells are both directly affected via reduced stimulation of their AR and indirectly affected through reduced stimulation of stromal cells. Normally, stromal cells produce various andromedins, such as IGF-1, which stimulate proliferation and inhibit apoptosis of epithelial and vascular cells in the prostate [28, 29]. It has been shown in mouse and rat prostate that paracrine IGF-1 signals from the stroma rapidly drops after castration [28, 30] and in patients reduction of IGF-1 levels in the tumor stroma after castration correlates with increased tumor cell apoptosis . Bone metastases are believed to show an attenuated response to castration therapy compared to primary prostate tumors. One of the reasons for this could be that the IGF-1 levels in the bone microenvironment, in contrast to the IGF-1 levels in prostate stroma, remain high also after androgen-deprivation and continue to stimulate the metastatic tumor cells. Therefore, inhibition of IGF-1 signaling meanwhile giving castration therapy may be a way to instantly reduce the survival effects mediated by bone-derived IGF-1 and thereby enhance effects of castration. Furthermore, continuous IGF-1R inhibition administered after castration therapy may be a way to postpone AR reactivation and development of castration-resistant PC (CRPC), as indicated by Plymate and co-workers . The combination of IGF-1R inhibition with inducers of apoptosis, such as cytostatic drugs or statins, may also provide great potential as novel treatment strategies for PC patients. Thus, high levels of IGF-1 present in the bone microenvironment may provide constant anti-apoptotic, pro-survival signals to the tumor cells, and probably lessen the effects of pro-apoptotic therapeutic drugs. By IGF-1R inhibition, we hypothesize that pro-survival signals can be diminished and apoptosis signals enhanced in metastatic tumor cells. In line with this idea, preclinical studies of multiple myeloma, lung cancer, and PC have shown that inhibition of IGF-1R signaling enhances the effects of radiotherapy and various chemotherapies [33–36].
Statins act in the mevalonate pathway and has been found to affect tumor cells both in cholesterol-dependent and cholesterol-independent ways. Cholesterol is an important element of specific plasma membrane structures known as lipid rafts . Inhibition of cholesterol levels by statins may lead to raft disruption, and deregulated cell signaling through the rafts [18, 38]. The PI3K-Akt pathway is highly active in many cancer cells and is a key regulator of cell survival . Simvastatin has been shown to inhibit Akt signaling and to induce apoptosis in tumor cells, including PC-3 cells . The PI3K-Akt pathway is furthermore activated down-stream of the IGF-1R and lipid rafts are essential for IGF-1R signaling , indicating that IGF-1R inhibitors and statins at least partly act by affecting the same intra-cellular pathways. In this study, we examined the expression levels of the IGF-1R and found that simvastatin was able to reduce the IGF-1R expression in PC-3 cells, which is similar to what others have previously shown both in PC and melanoma cell lines [23, 24]. In 22Rv1 cells, however, the IGF-1R expression was not reduced by simvastatin treatment. Still, the inhibitory effects of simvastatin in the 22Rv1 cells were prominent, and we examined if simvastatin had any effect on the AR expression level as have been recently indicated by others . Most importantly, simvastatin was able to reduce the mRNA and protein expression level of the AR-V7 splice variant that is supposed to possess constitutive activity, while the levels of the full length AR were not obviously reduced. Expression of ligand-independent AR variants is believed to contribute to the development and growth of CRPC [26, 41–43], and it is thus possible that statin treatment could be of benefit for patients expressing AR variants, as a complement to anti-androgen therapies targeting the full length receptor.
In conclusion, we show that the bone is a favorable growth environment for PC cells that partly could be attributed to bone-derived IGF-1. Tumor cells enhance the IGF-1 release from bone and this probably originates both from increased IGF-1 synthesis in bone cells and from increased bone resorption, as previously indicated . Administration of the IGF-1R inhibitor NVP-AEW541 to PC cells in co-culture with bone intensifies growth inhibiting effects of simvastatin, and indicates that IGF-1 inhibition may be a way to strengthen effects of pro-apoptotic therapies of PC bone metastases. This possibility needs to be further tested in pre-clinical models.
The PC-3 and 22Rv1 tumor cell lines were purchased from American Type Culture Collection (ATCC) and maintained in RPMI 1640 (Invitrogen, Stockholm, Sweden) supplemented with 10 % fetal bovine serum (FBS; Invitrogen) and 50 μg/ml gentamicin (Invitrogen), at 37 °C in a humified atmosphere with 5 % CO2. In all experiments this culture medium was used to seed the cells. After 24 h the culture medium was replaced with bone culture medium; αMEM (Invitrogen) supplemented with 0.1 % albumin, and cells were incubated for an additional 24 h. After this the medium was replaced with new bone culture medium with supplements as described in each experiment. Simvastatin (SIGMA-ALDRICH) and NVP-AEW541 (Novartis Pharmaceuticals) were handled and simvastatin activated according to manufacturer’s description. Cells were treated with simvastatin and NVP-AEW541 according to the dosages and times indicated in the experiments.
The co-culture model was previously described in . Tumor cells were seeded in culture medium (described above) at concentrations of 105 cells/well (PC-3) and 1.5 × 105 cells/well (22Rv1) in 6-well plates. After 24 h culture medium was replaced with bone culture medium; αMEM (Invitrogen) supplemented with 0.1 % albumin, and cells were incubated for additional 24 h. Thereafter, cells received new bone culture medium (4 ml/well) and after 3–4 h calvarial bones were placed on metal grids in the wells, separating the bones from the tumor cells but still allowing signaling through the medium between the two compartments. The calvarial bones were dissected from 6 to 7-day-old-mice, cut into halves, pre-incubated with indomethacin (10−6) in bone culturing medium for 24 h and subsequently washed according to Lerner et al. .
Calvarial bones for co-culture experiments were obtained from CsA mice from our own inbred colony. All animal experiments were approved by the local ethical committee for animal research.
Neutralization of calvariae-released IGF-1 in co-cultures was performed using an anti-mouse IGF-1 antibody (R&D Systems, Abingdon, UK). The neutralizing antibody was added to the cultures when calvariae were placed in the wells, at a concentration of 0.3 μg/ml. After 72 h of co-culture cell growth was determined.
At the end of the co-culture experiments cells were harvested with trypsin, mixed with 0.4 % trypan blue (at a 1:1 dilution) and number of viable, non-stained cells was determined using a Countess™ automated cell counter (Invitrogen).
Tumor cell viability was determined by measuring the conversion of 3 (4,5-dimethythiazozyl-2)-2,5 diphenyl tetrazolium bromide (MTT) to purple formazan product using the Cell Proliferation Kit I (Roche Diagnostics, Bromma, Sweden) according to the manufacturer’s instructions.
A human Phospho-RTK Array (R&D Systems) detecting phosphorylation status of 42 different RTKs was used to screen for bone-induced RTK activation in tumor cells. Tumor cells were seeded as described above (see ‘Co-culture model’) and grown in bone culturing medium for 72 h. Medium was removed and tumor cells were stimulated with calvariae-conditioned medium (from calvariae cultured in bone culture medium for 72 h) for 10 min and then immediately placed on ice. Cells were washed with cold PBS and solubilized in lysis buffer containing 1 % Igepal CA-630 (Sigma-Aldrich, ST. Louis, MO), 20 mM Tris–HCl (pH 8.0), 137 mM NaCl, 10 % glycerol, 2 mM EDTA, Complete Protease Inhibitor (Roche Diagnostics) and 10 μL/mL Halt™ Phosphatase Inhibitor Cocktail (Thermo Scientific, Rockford, IL). Samples were incubated on ice for 30 min and centrifuged (14,000 x g for 5 min) to isolate the supernatants. Protein concentration was determined using BCA Protein Assay Kit (Thermo Scientific) and the Phospho-RTK array was performed according to the manufacturer’s instructions using 100 μg of PC-3 samples and 150 μg of 22Rv1 samples. RTK phosphorylations were detected using the ELC Plus Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK). Average pixel density was determined using the Quantity-one software (Bio-Rad Laboratories, Hercules, CA) and average pixel density of duplicate spots was normalized to positive control spots.
Tumor cells and calvarial bones were cultured as described above (see ‘Co-culture model’). After 72 h culture medium was harvested, particulates removed by centrifugation, and samples stored at −20 °C. Tumor cell and calvarial secretion of IGF-1 was measured by the human (DG100) and mouse (MG100) specific IGF-1 Quantikine ELISAs, respectively, (R&D Systems) according to protocols.
After 72 h of co-culture, tumor cells were harvested and washed once in PBS. Approximately 200,000 cells were placed in round-bottom 96-well plates and apoptosis was assessed using the FITC Annexin-V Apoptosis Detection Kit (BD Pharmingen) according to manufacturer’s instructions. Staining was determined by flow cytometry (FACSCalibur, BD Biosciences FACS) and analyzed using CellQuest software (BD).
Total RNA was extracted from the tumor cells using the RNAqueous kit (Ambion, Huntingdon, UK) according to the manufacturer’s instructions. Total RNA was DNase-treated with TURBO DNase (Ambion) and RNA concentrations were determined using a Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, DE). Using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems), 500 ng of RNA was reverse transcribed. Resulting cDNA samples were diluted 10 times and stored at −20 °C.
Quantitative real-time PCR of RPL13, IGF-1, IGF-1R, AR and AR-V7 (Table 1) mRNA levels was performed using the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA) and the Power SYBR Green PCR Master Mix (Applied Biosystems) according to protocol. Ct values were analyzed with the standard curve method (User Bulletin #2, Applied Biosystems) and IGF-1, IGF-1R, AR and AR-V7 mRNA levels were normalized to house-keeping gene RPL13 mRNA levels.
Proteins were extracted using 1 % Igepal CA-630 (Sigma-Aldrich), 20 mM Tris–HCl (pH 8.0), 137 mM NaCl, 10 % glycerol, 2 mM EDTA and Complete Protease Inhibitor (Roche Diagnostics) and protein concentration was determined by the BCA Protein assay (Pierce Chemical Co., IL, USA). Samples (4–20 μg protein) were separated by 7.5 % SDS-PAGE under reducing conditions and subsequently transferred to PVDF membranes. Membranes were blocked in 5 % milk before incubated with the anti-AR antibody over night in 4 °C (N-20, Santa Cruz Biotechnology, Santa Cruz, CA, diluted 1:500 in 1 % milk/PBST,), in order to detect the full length AR and AR variants with an intact N-terminal domain. Secondary anti-rabbit IgG antibody (Dako, Glostrup, Denmark, diluted 1:20 000 in 2.5 % milk) was applied after washing in PBST and incubated for 1 h in RT. Protein expression was visualized after extensive washing using the ECL Advanced detection kit (GE Healthcare, Buckinghamshire, UK) and quantified with a ChemiDoc scanner and the Quantity One 4 software (Bio-Rad Laboratories). IGF-1R was detected using the AF-305-NA antibody (diluted 1:500, R&D Systems, Abington, UK), secondary anti-goat IgG antibody (diluted 1:20 000, Dako), and the ECL Plus detection kit (GE Healthcare). Membranes were stripped and re-analyzed as above with primary antibody against actin (diluted 1:8000, SIGMA, Saint Louis. Missouri). The relative AR levels were adjusted for the corresponding actin levels.
In each experiment, data was expressed in relation to control values (with control mean value set to 1) and showed as mean ± SD. Results were analysed using ANOVA and Student’s t-test. A P-value below 0.05 was considered statistically significant.
This work was supported by grants from the Swedish Cancer Society, the Cancer Research Foundation in Northern Sweden, Lion’s Cancer Research Foundation, regional ALF support from Västerbotten County Council, and Umeå University. NVP-AEW541 was kindly provided by Novartis Pharmaceuticals.
|1..||Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat RevYear: 200127316517610.1053/ctrv.2000.021011417967|
|2..||Linkhart TA,Mohan S,Baylink DJ. Growth factors for bone growth and repair: IGF, TGF beta and BMPBoneYear: 1996191 Suppl1S12S10.1016/S8756-3282(96)00138-X8830994|
|3..||Garnero P,Buchs N,Zekri J,Rizzoli R,Coleman RE,Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancerBr J CancerYear: 200082485886410.1054/bjoc.1999.101210732759|
|4..||Nordstrand A,Nilsson J,Tieva A,Wikstrom P,Lerner UH,Widmark A. Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cellsClin Exp MetastasisYear: 200926894595310.1007/s10585-009-9285-419728119|
|5..||Roddam AW,Allen NE,Appleby P,Key TJ,Ferrucci L,Carter HB,Metter EJ,Chen C,Weiss NS,Fitzpatrick A,Hsing AW,Lacey JV Jr,Helzlsouer K,Rinaldi S,Riboli E,Kaaks R,Janssen JA,Wildhagen MF,Schroder FH,Platz EA,Pollak M,Giovannucci E,Schaefer C,Quesenberry CP Jr,Vogelman JH,Severi G,English DR,Giles GG,Stattin P,Hallmans G,Johansson M,Chan JM,Gann P,Oliver SE,Holly JM,Donovan J,Meyer F,Bairati I,Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studiesAnn Intern MedYear: 2008149746147110.7326/0003-4819-149-7-200810070-0000618838726|
|6..||Rowlands MA,Gunnell D,Harris R,Vatten LJ,Holly JM,Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysisInt J CancerYear: 2009124102416242910.1002/ijc.2420219142965|
|7..||Hewish M,Chau I,Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicineRecent Pat Anticancer Drug DiscovYear: 200941547210.2174/15748920978700251519149688|
|8..||Turney BW,Turner GD,Brewster SF,Macaulay VM. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progressionBJU IntYear: 201110791488149910.1111/j.1464-410X.2010.09556.x20840329|
|9..||de Bono JS,Attard G,Adjei A,Pollak MN,Fong PC,Haluska P,Roberts L,Melvin C,Repollet M,Chianese D,Connely M,Terstappen LW,Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptorClin Cancer ResYear: 200713123611361610.1158/1078-0432.CCR-07-026817575225|
|10..||Ryan CJ,Haqq CM,Simko J,Nonaka DF,Chan JM,Weinberg V,Small EJ,Goldfine ID. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancerUrol OncolYear: 200725213414010.1016/j.urolonc.2006.07.01917349528|
|11..||Hellawell GO,Turner GD,Davies DR,Poulsom R,Brewster SF,Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic diseaseCancer ResYear: 200262102942295012019176|
|12..||Parrizas M,Saltiel AR,LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathwaysJ Biol ChemYear: 1997272115416110.1074/jbc.272.1.1548995241|
|13..||Kulik G,Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor IMol Cell BiolYear: 19981811671167189774684|
|14..||Grothey A,Voigt W,Schober C,Muller T,Dempke W,Schmoll HJ. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumorsJ Cancer Res Clin OncolYear: 19991253–416617310.1007/s00432005025910235470|
|15..||Buck E,Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancerExpert Opin Investig DrugsYear: 201120560562110.1517/13543784.2011.55850121446886|
|16..||Heidegger I,Pircher A,Klocker H,Massoner P. Targeting the insulin-like growth factor network in cancer therapyCancer Biol TherYear: 201111870170710.4161/cbt.11.8.1468921311212|
|17..||Thysell E,Surowiec I,Hornberg E,Crnalic S,Widmark A,Johansson AI,Stattin P,Bergh A,Moritz T,Antti H,Wikstrom P. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterolPLoS OneYear: 2010512e1417510.1371/journal.pone.001417521151972|
|18..||Zhuang L,Kim J,Adam RM,Solomon KR,Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenograftsJ Clin InvestYear: 2005115495996815776112|
|19..||Hoque A,Chen H,Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cellsCancer Epidemiol Biomark PrevYear: 2008171889410.1158/1055-9965.EPI-07-0531|
|20..||Papadopoulos G,Delakas D,Nakopoulou L,Kassimatis T. Statins and prostate cancer: molecular and clinical aspectsEur J CancerYear: 201147681983010.1016/j.ejca.2011.01.00521354784|
|21..||Garcia-Echeverria C,Pearson MA,Marti A,Meyer T,Mestan J,Zimmermann J,Gao J,Brueggen J,Capraro HG,Cozens R,Evans DB,Fabbro D,Furet P,Porta DG,Liebetanz J,Martiny-Baron G,Ruetz S,Hofmann F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinaseCancer CellYear: 20045323123910.1016/S1535-6108(04)00051-015050915|
|22..||Scotlandi K,Manara MC,Nicoletti G,Lollini PL,Lukas S,Benini S,Croci S,Perdichizzi S,Zambelli D,Serra M,Garcia-Echeverria C,Hofmann F,Picci P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumorsCancer ResYear: 20056593868387610.1158/0008-5472.CAN-04-319215867386|
|23..||Carlberg M,Dricu A,Blegen H,Wang M,Hjertman M,Zickert P,Hoog A,Larsson O. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growthJ Biol ChemYear: 199627129174531746210.1074/jbc.271.29.174538663239|
|24..||Sekine Y,Furuya Y,Nishii M,Koike H,Matsui H,Suzuki K. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptorBiochem Biophys Res CommunYear: 2008372235636110.1016/j.bbrc.2008.05.04318489904|
|25..||Yokomizo A,Shiota M,Kashiwagi E,Kuroiwa K,Tatsugami K,Inokuchi J,Takeuchi A,Naito S. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cellsProstateYear: 201171329830410.1002/pros.2124320717902|
|26..||Dehm SM,Tindall DJ. Alternatively spliced androgen receptor variantsEndocr Relat CancerYear: 2011185R183R19610.1530/ERC-11-014121778211|
|27..||Ohlson N,Wikstrom P,Stattin P,Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatmentProstateYear: 200562430731510.1002/pros.2013915389788|
|28..||Ohlson N,Bergh A,Persson ML,Wikstrom P. Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its effects in the ventral prostate in miceProstateYear: 200666161687169710.1002/pros.2036816998818|
|29..||Cohen P,Peehl DM,Lamson G,Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cellsJ Clin Endocrinol MetabYear: 199173240140710.1210/jcem-73-2-4011713219|
|30..||Nickerson T,Pollak M,Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5EndocrinologyYear: 1998139280781010.1210/en.139.2.8079449659|
|31..||Ohlson N,Bergh A,Stattin P,Wikstrom P. Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levelsProstateYear: 2007671324010.1002/pros.2048016998819|
|32..||Plymate SR,Haugk K,Coleman I,Woodke L,Vessella R,Nelson P,Montgomery RB,Ludwig DL,Wu JD. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancerClin Cancer ResYear: 200713216429643910.1158/1078-0432.CCR-07-064817975155|
|33..||Allen GW,Saba C,Armstrong EA,Huang SM,Benavente S,Ludwig DL,Hicklin DJ,Harari PM. Insulin-like growth factor-I receptor signaling blockade combined with radiationCancer ResYear: 20076731155116210.1158/0008-5472.CAN-06-200017283150|
|34..||Descamps G,Gomez-Bougie P,Venot C,Moreau P,Bataille R,Amiot M. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45Br J CancerYear: 2009100236636910.1038/sj.bjc.660483919165200|
|35..||Baumann P,Hagemeier H,Mandl-Weber S,Franke D,Schmidmaier R. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001Anticancer DrugsYear: 200920425926610.1097/CAD.0b013e328328d18b19240643|
|36..||Wu JD,Haugk K,Coleman I,Woodke L,Vessella R,Nelson P,Montgomery RB,Ludwig DL,Plymate SR. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumorsClin Cancer ResYear: 20061220 Pt 16153616010.1158/1078-0432.CCR-06-044317062692|
|37..||Lingwood D,Simons K. Lipid rafts as a membrane-organizing principleScienceYear: 20103275961465010.1126/science.117462120044567|
|38..||Li YC,Park MJ,Ye SK,Kim CW,Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agentsAm J PatholYear: 200616841107111810.2353/ajpath.2006.05095916565487|
|39..||Altomare DA,Testa JR. Perturbations of the AKT signaling pathway in human cancerOncogeneYear: 200524507455746410.1038/sj.onc.120908516288292|
|40..||Hong S,Huo H,Xu J,Liao K. Insulin-like growth factor-1 receptor signaling in 3T3-L1 adipocyte differentiation requires lipid rafts but not caveolaeCell Death DifferYear: 200411771472310.1038/sj.cdd.440140515002041|
|41..||Hu R,Dunn TA,Wei S,Isharwal S,Veltri RW,Humphreys E,Han M,Partin AW,Vessella RL,Isaacs WB,Bova GS,Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancerCancer ResYear: 2009691162210.1158/0008-5472.CAN-08-276419117982|
|42..||Guo Z,Yang X,Sun F,Jiang R,Linn DE,Chen H,Kong X,Melamed J,Tepper CG,Kung HJ,Brodie AM,Edwards J,Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growthCancer ResYear: 20096962305231310.1158/0008-5472.CAN-08-379519244107|
|43..||Hornberg E,Ylitalo EB,Crnalic S,Antti H,Stattin P,Widmark A,Bergh A,Wikstrom P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survivalPLoS OneYear: 201164e1905910.1371/journal.pone.001905921552559|
|44..||Lerner UH. Modifications of the mouse calvarial technique improve the responsiveness to stimulators of bone resorptionJ Bone Miner ResYear: 19872537538310.1002/jbmr.56500205043455622|
Primers used for quantitative real-time PCR
|Gene||Forward primer||Reverse primer|
|RPL13||5′-CCG CTC TGG ACC GTC TCA A-3′||5′-CCT GGT ACT TCC AGC CAA CCT-3′|
|IGF-1||5′-CAG CAG TCT TCC AAC CCA AT-3′||5′- TGG TGT GCA TCT TCA CCT TC-3′|
|IGF-1R||5′-AGG AAC AAC GGG GAG AGA GC-3′||5′-ACC GGT GCC AGG TTA TGA TG-3′|
|AR||5′-CCA TCT TGT CGT CTT CGG AAA TGT TAT GAA GC-3′||5′-AGC TTC TGG GTT GTC TCC TCA GTG G-3′|
|AR-V7||5′-CCA TCT TGT CGT CTT CGG AAA TGT TAT GAA GC-3′||5′-TTT GAA TGA GGC AAG TCA GCC TTT CT-3′|
Keywords: Keywords Prostate cancer, Bone metastases, IGF-1R, Simvastatin, Cholesterol.
Previous Document: Learning from an epidemiological, population-based study on prescribed medicine use in adults.
Next Document: Capsule function following anterior dislocation: implications for diagnosis of shoulder instability.